niclosamide has been researched along with Idiopathic Pulmonary Fibrosis in 2 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Idiopathic Pulmonary Fibrosis: A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide (Ncl) is an antihelminthic drug approved by FDA, which has been reported to have pleiotropic pharmacological activities in recent years, but it's almost complete insolubility in water limits its clinical application." | 1.91 | Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro. ( Gan, C; Gong, C; Liu, H; Ouyang, L; Tan, Z; Wang, Y; Xiang, Z; Xie, Y; Yao, Y; Ye, T, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pei, X | 1 |
| Zheng, F | 1 |
| Li, Y | 1 |
| Lin, Z | 1 |
| Han, X | 1 |
| Feng, Y | 1 |
| Tian, Z | 1 |
| Ren, D | 1 |
| Cao, K | 1 |
| Li, C | 1 |
| Gan, C | 1 |
| Wang, Y | 1 |
| Xiang, Z | 1 |
| Liu, H | 1 |
| Tan, Z | 1 |
| Xie, Y | 1 |
| Yao, Y | 1 |
| Ouyang, L | 1 |
| Gong, C | 1 |
| Ye, T | 1 |
2 other studies available for niclosamide and Idiopathic Pulmonary Fibrosis
| Article | Year |
|---|---|
Niclosamide Ethanolamine Salt Alleviates Idiopathic Pulmonary Fibrosis by Modulating the PI3K-mTORC1 Pathway.
Topics: Animals; Bleomycin; Ethanolamine; Hydroxyproline; Idiopathic Pulmonary Fibrosis; Mechanistic Target | 2022 |
Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro.
Topics: Alveolar Epithelial Cells; Animals; Extracellular Matrix; Idiopathic Pulmonary Fibrosis; Lung Diseas | 2023 |